This project has two major components- preclinical and clinical. I am currently collaborating with members of NINDS in obtaining new agents and testing them in a nonhuman primate model prior to evaluating these agents in pediatric patients. The ideal agent for testing is a nonneurotoxic agent with poor blood:brain barrier penetration that has demonstrated activity in vitro against CNS tumor cell lines. In the past year, we have evaluated a potential agent and have plans to evaluate a number of additional agents. IL-13 PE has undergone extensive preclinical testing in the Surgical Neurology Branch. It has been used in national consortia studies for administration to adult patients with supratentorial gliomas. Recently, data has become available from autopsy specimens from children with diffuse pontine gliomas, demonstrating extensive expression of IL13 within these tumors. We are currently accruing to an IRB-approved protocol within NINDS.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010800-07
Application #
8763225
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
2013
Total Cost
$51,356
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Chittiboina, Prashant; Heiss, John D; Warren, Katherine E et al. (2014) Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J Neurosurg Pediatr 13:276-82